NetworkNewsWire Announces Publication on the Use of Cannabinoids for Pain Management and other Medical Applications  

NEW YORK, Dec. 07, 2017 (GLOBE NEWSWIRE) — via NetworkNewsWire (“NNW”), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems.

The publication, titled, “Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management,” reviews InMed’s cannabinoid manufacturing process and its potential in pain management.

To view the full publication, visit:

“Other biopharmaceutical companies may produce cannabinoids in the laboratory using chemical synthesis, but there’s a litany of drug development efforts with synthetic molecules that have failed. The proprietary biosynthesis process used by InMed Pharmaceuticals, Inc.’s (CSE:IN) (OTCQB:IMLFF) is unique. Producing cannabinoids that are identical to naturally occurring compounds is transformative for drug development. By using its proprietary process, InMed is able to manufacture exact cannabinoid replicas for use in research. This novel breakthrough gives InMed scientists the ability to manufacture all 90+ cannabinoid compounds identical to those found in nature and the ability to consistently, reliably and accurately test efficacy and safety. In addition, InMed’s cost-effective biosynthesis process enhances production, purification, and quality control as opposed to other chemical manufacturing methods. InMed’s biopharmaceutical approach to the production of pharmaceutical grade, bio-identical cannabinoids is disruptive in the development of pharmaceutical cannabinoids for research and drug creation. The company’s high-yield manufacturing process also provides simpler scale-up and systems optimization, as well as the production of minor cannabinoids that are economically impractical to extract from plant sources.

“To protect this invaluable asset, InMed has filed a provisional patent for the biosynthesis of cannabinoids (, and the company continues to use the technology to expand its pipeline for treating a variety of medical conditions.

“InMed’s cannabinoid biosynthesis process is complemented by its bioinformatics drug and disease targeting tool. Bioinformatics is a high-efficiency, computer-assisted approach to predicting the therapeutic potential and medicinal properties of individual cannabinoids against particular medical conditions. InMed’s proprietary approach applies comprehensive algorithms to integrate the data from various bioinformatics databases, including a vast database of the chemical structures of approved pharmaceuticals, with InMed’s proprietary cannabinoid database and know-how.”

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company. For more information, visit

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications Contact:

Michael McCarthy
Managing Director
NetworkNewsWire (NNW)
New York, New York 
212.418.1217 Office

Share this post